crizotinib

0:04:10

Crizotinib Resistance in ALK+ NSCLC

0:01:27

Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLC

0:00:56

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

0:04:58

How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

0:07:07

ROS1 Treatment Options: Crizotinib and Entrectinib - 2022 Program: Targeted Therapies Forum

0:05:19

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

0:02:46

Estudo Alectinib versus Crizotinib em primeira linha de tratamento - ASCO 2017

0:07:02

Crizotinib for ALK-Rearranged NSCLC

0:22:10

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer

0:04:38

Patterns of Progression on Crizotinib for ALK+ NSCLC

0:00:44

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

0:05:28

CROWN study: lorlatinib vs crizotinib in 1L NSCLC

0:01:17

Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer

0:03:24

Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

0:02:45

Crizotinib treatment in lung adenocarcinoma patient with ROS1 fusion – Video abstract ID 136297

0:02:52

Q&A: Cabozantinib for ROS1 after Progression on Crizotinib - Targeted Therapies in Lung Cancer 2023

0:35:27

Expanded Clinical Research Opportunities for Crizotinib Identified

0:04:00

ALTA-1L: final overall survival results of brigatinib vs crizotinib for ALK+ lung cancer

0:02:03

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

0:02:15

New ALK Inhibitor Drugs vs Xalkori (Crizotinib) for ALK+ Lung Cancer Patients

0:02:18

ALTA-1L: brigatinib is superior to crizotinib in ALK+ NSCLC

0:04:38

ALTA II: Brigatinib in Crizotinib-Resistant ALK+ NSCLC

0:02:40

Dr. Felipe Ades - Quais são os efeitos colaterais do crizotinib? O que fazer nestes casos?

0:02:09

ALTA-1L: brigatinib vs crizotinib in ALK+ aNSCLC